Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma has won a legal challenge in the US to prevent Ranbaxy Laboratories from launching a generic version of its prostate drug Flomax.
Subscribe to our email newsletter
Japan’s Astellas Pharma has a US patent on Flomax, which is used for the treatment of benign prostatic hyperplasia, until October 27, 2009.
Astellas, and Boehringer Ingelheim of Germany, together market Flomax in the US. The court decision to prevent Ranbaxy from producing a generic version of the drug was made in New Jersey, US.